Fend Falko, Dirnhofer Stefan, Egan Caoimhe, Song Sophie, Wang Zhe, Li Xiaoqiu, Liu Weiping, Xiao Wenbin, Emile Jean-Francois, Goodlad John, Lorsbach Robert
Institute of Pathology and Neuropathology and Comprehensive Cancer Center, Tübingen University Hospital, Liebermeisterstrasse 8, 72076, Tübingen, Germany.
Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Virchows Arch. 2025 Apr 10. doi: 10.1007/s00428-025-04096-4.
Reactive and clonal proliferations of histiocytes (macrophages/dendritic cells) represent a broad spectrum of disorders, which can affect virtually any organ of the body. The clinical spectrum ranges from benign, localized and self-limiting manifestations to severe multi-system disease. Hemophagocytic lymphohistiocytosis (HLH) is a frequently life-threatening, systemic hyperinflammatory process triggered by massive cytokine release by activated, reactive macrophages. Familial and secondary forms of HLH are discerned. Histiocytoses are clonal inflammatory myeloid disorders characterized by proliferations of mature histiocytes/macrophages and dendritic cells with recurrent kinase-activating mutations which result in constitutive activation of the ERK signaling pathway. Although traditionally subclassified according to the phenotype of the lesional cells, the clonal cells can show significant plasticity, and the occurrence of mixed histiocytoses is increasingly recognized. This is in part due to their derivation from a myeloid progenitor cell and explains the frequent association with clonal hematopoiesis or overt myeloid neoplasms in adults. At the joint Workshop of the Chinese Society of Hematopathology, the European Association for Haematopathology and the Society for Hematopathology on histiocytic/dendritic cell proliferations, neoplasms, and their mimics in Hefei, China, April 2024, in sessions 1 and 2 a total of 8 cases of HLH, 9 cases of reactive histiocytic proliferations and 40 cases of histiocytoses were submitted and reviewed by the panel. The latter included cases of LCH, indeterminate cell histiocytosis, Erdheim Chester disease, juvenile xanthogranuloma, Rosai Dorfman disease, multicentric reticulohistiocytosis, ALK-positive histiocytosis, and mixed histiocytoses. The present report summarizes important findings and open questions arising from discussing the workshop cases.
组织细胞(巨噬细胞/树突状细胞)的反应性和克隆性增殖代表了一系列广泛的疾病,几乎可累及身体的任何器官。临床谱范围从良性、局限性和自限性表现到严重的多系统疾病。噬血细胞性淋巴组织细胞增生症(HLH)是一种常危及生命的全身性高炎症过程,由活化的反应性巨噬细胞大量释放细胞因子引发。HLH可分为家族性和继发性形式。组织细胞增多症是克隆性炎症性髓系疾病,其特征是成熟组织细胞/巨噬细胞和树突状细胞增殖,并伴有复发性激酶激活突变,导致ERK信号通路的组成性激活。尽管传统上根据病变细胞的表型进行亚分类,但克隆细胞可表现出显著的可塑性,混合性组织细胞增多症的发生越来越受到认可。这部分是由于它们起源于髓系祖细胞,并解释了在成人中与克隆性造血或明显的髓系肿瘤的频繁关联。在中国合肥举行的中国血液病理学学会、欧洲血液病理学协会和血液病理学学会关于组织细胞/树突状细胞增殖、肿瘤及其模仿物的联合研讨会上,在2024年4月的第1和第2场会议中,共有8例HLH、9例反应性组织细胞增殖和40例组织细胞增多症病例被提交并由专家小组进行了审查。后者包括朗格汉斯细胞组织细胞增多症、未定型细胞组织细胞增多症、 Erdheim-Chester病、幼年性黄色肉芽肿、Rosai-Dorfman病、多中心网状组织细胞增多症、ALK阳性组织细胞增多症以及混合性组织细胞增多症病例。本报告总结了讨论研讨会病例所产生的重要发现和未解决的问题。